+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Sale

Liquid Biopsy Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904966
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Liquid Biopsy Market is projected to reach USD 7.39 Billion in 2026. It is expected to continue growing at a CAGR of 17.39%, reaching USD 18.27 Billion by 2032.

Liquid biopsy is redefining precision oncology by enabling analysis of circulating tumor DNA, circulating tumor cells, cell-free DNA, RNA, methylation signatures, exosomes, and other analytes from blood or other body fluids. Unlike conventional tissue biopsy, liquid biopsy can support less invasive sampling, longitudinal monitoring, and faster molecular profiling when tissue is unavailable, insufficient, or difficult to access.

The field has moved from exploratory research to clinical utility, supported by U.S. FDA-authorized companion diagnostics, broad use of next-generation sequencing, and increasing guideline recognition in advanced cancers. Demand is strongest in therapy selection, resistance monitoring, minimal residual disease assessment, recurrence surveillance, and emerging multi-cancer early detection applications, where evidence quality, analytical sensitivity, and clinical validity remain decisive adoption factors.

Transformative Shifts in Liquid Biopsy

The liquid biopsy landscape is shifting from single-gene mutation testing toward broader multi-analyte, multi-omics platforms. Laboratories and diagnostics developers are combining ctDNA mutation profiling with methylation, fragmentomics, epigenomic signals, proteomics, and AI-enabled interpretation to improve sensitivity and clinical relevance across cancer stages.

Regulatory and reimbursement expectations are also transforming adoption. FDA-cleared and FDA-approved tests have strengthened physician confidence, while payers increasingly require evidence of clinical utility, outcome improvement, and cost-effectiveness. At the same time, decentralized blood collection, biopharma partnerships, and clinical trial stratification are expanding use beyond late-stage oncology into recurrence risk, treatment response, and screening, particularly in settings where repeat tissue biopsy is clinically impractical.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the impact of liquid biopsy by improving signal detection in low-abundance tumor fractions, reducing sequencing noise, and supporting interpretation of complex genomic and epigenomic patterns. Machine learning models are increasingly used for variant calling, methylation classification, tumor-origin prediction, and risk stratification, especially where early-stage disease produces limited ctDNA.

AI also supports operational scalability through automated quality control, bioinformatics workflow optimization, laboratory workflow prioritization, and clinical decision support. However, adoption depends on transparent validation, bias assessment across populations, data governance, cybersecurity, and compliance with evolving AI and medical device regulations. The most defensible AI-enabled liquid biopsy strategies are those anchored in prospective clinical evidence, reproducible model performance, and traceable analytical validation.

Key Regional Insights: Global Liquid Biopsy Adoption

North America remains a leading liquid biopsy region due to advanced oncology infrastructure, established molecular pathology networks, FDA regulatory pathways, major clinical trial activity, and payer engagement around companion diagnostics and genomic profiling. The United States anchors adoption through precision medicine programs, cancer center networks, and integration of liquid biopsy into oncology drug development, while Canada shows steady implementation through provincial oncology systems, centralized laboratory models, and evidence-based reimbursement review.

Europe is shaped by strong academic oncology, the EU In Vitro Diagnostic Regulation, and national health technology assessment processes that emphasize clinical validity, clinical utility, and quality management. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in genomic medicine, local sequencing capacity, cancer screening infrastructure, and advanced oncology care. Latin America is progressing through private-sector testing, reference-lab partnerships, and expanding molecular oncology awareness, while the Middle East is accelerating precision oncology through national transformation programs, advanced hospital systems, and investment in genomic medicine. Africa remains earlier in adoption, with opportunities centered on access, sample logistics, oncology workforce development, laboratory accreditation, and regional reference laboratories that can improve availability of liquid biopsy testing.

Key Group Insights: Strategic Liquid Biopsy Clusters

Within ASEAN, liquid biopsy demand is supported by rising cancer burden, medical tourism hubs, expanding private diagnostics networks, and improving access to oncology specialists, although reimbursement, laboratory standardization, and cross-country regulatory alignment remain uneven. The GCC is investing in precision medicine, population health, advanced oncology centers, and digital health infrastructure, creating favorable conditions for premium liquid biopsy services, localized validation, and partnerships with diagnostic providers and academic hospitals.

The European Union is defined by IVDR compliance, cross-border cancer research, quality assurance requirements, and evidence-led reimbursement, making analytical validation and demonstrated clinical utility essential for scale. BRICS countries are important growth engines because of large patient populations, local sequencing capabilities, government interest in biotechnology self-sufficiency, and expanding cancer care capacity. G7 markets lead in clinical trial adoption, regulatory sophistication, reimbursement scrutiny, and oncology guideline integration, while NATO countries benefit from overlapping healthcare modernization, biomedical research funding, laboratory interoperability initiatives, and secure data infrastructure that can strengthen genomic medicine and liquid biopsy implementation.

Key Country Insights: Priority Liquid Biopsy Markets

The United States leads commercialization through FDA-authorized assays, companion diagnostic use, oncology guideline adoption, and biopharma use in clinical trials. Canada is advancing through centralized cancer programs, provincial testing pathways, and evidence-based assessment, while Mexico and Brazil show growing private-lab adoption, reference laboratory partnerships, and increasing interest in expanding molecular oncology access. The United Kingdom, Germany, France, Italy, and Spain are building liquid biopsy use through national genomics strategies, cancer networks, molecular tumor boards, and health technology assessment discipline; Russia’s market is shaped by domestic testing capacity, regional oncology infrastructure, and constrained access to some international technologies.

China is scaling local liquid biopsy innovation through high-volume oncology demand, domestic sequencing capacity, and regulatory attention to advanced diagnostics. India is expanding access through urban oncology centers, cost-sensitive laboratory models, and rising demand for precision cancer care. Japan and South Korea benefit from strong precision medicine ecosystems, regulatory maturity, advanced cancer care infrastructure, and active oncology research networks. Australia supports adoption through guideline-driven oncology practice, academic research, established molecular pathology networks, and structured evaluation of new diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications with clear clinical utility, such as therapy selection in advanced cancer, resistance monitoring, and measurable residual disease programs backed by prospective evidence. Product roadmaps should align assay performance with intended use, including limits of detection, tumor fraction requirements, sample handling specifications, turnaround time, reporting clarity, and interpretability for oncologists.

Commercial success will depend on payer-ready evidence, regulatory-quality validation, laboratory accreditation, and partnerships with cancer centers, biopharma sponsors, and reference laboratories. Organizations should invest in interoperable bioinformatics, transparent AI governance, diverse clinical datasets, real-world evidence generation, and patient-friendly blood collection models. Regional strategies should be tailored to reimbursement maturity, oncology infrastructure, local regulatory requirements, and clinical workflow readiness rather than relying on one global commercialization template.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, publicly available, and industry-recognized sources. Inputs include regulatory databases and announcements from agencies such as the U.S. FDA and European authorities; clinical guidance from oncology organizations including NCCN, ASCO, and ESMO; peer-reviewed oncology and molecular diagnostics literature; clinical trial registries; reimbursement updates; public health datasets from sources such as WHO and OECD; and documented technology developments in next-generation sequencing, ctDNA analysis, methylation profiling, and AI-enabled bioinformatics.

Insights are triangulated across regulatory milestones, clinical adoption signals, technology trends, regional healthcare infrastructure, guideline evolution, reimbursement conditions, and peer-reviewed evidence. The analysis excludes unsupported market claims and emphasizes evidence-backed interpretation of liquid biopsy applications, including companion diagnostics, ctDNA profiling, minimal residual disease, recurrence monitoring, treatment response assessment, and early detection research.

Conclusion: Evidence-Led Growth in Liquid Biopsy

Liquid biopsy has become a central pillar of precision oncology because it offers a practical route to real-time molecular insight with lower procedural burden than tissue biopsy. Its strongest current value lies in therapy selection, resistance detection, and longitudinal monitoring, while early cancer detection and multi-cancer screening remain high-potential areas requiring rigorous validation, careful implementation, and clear evidence of clinical benefit.

The next phase of leadership will be defined by clinical evidence, regulatory credibility, AI-enabled analytical performance, reimbursement alignment, and equitable access. Organizations that combine scientifically validated assays with payer-aligned outcomes, regional execution, robust laboratory quality systems, and trustworthy data infrastructure will be best positioned to shape the future of liquid biopsy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Precision-oncology treatment selection and evolving resistance
4.3.1.2. Serial residual-disease and recurrence surveillance
4.3.1.3. Investment in blood-based early detection and screening
4.3.1.4. Rising cancer burden and unmet diagnostic need
4.3.2. Key Restraints
4.3.2.1. Unresolved clinical utility and follow-up economics in broad screening
4.3.2.2. Selective reimbursement and indication-specific evidence requirements
4.3.2.3. Biological signal limitations and continued tissue complementarity
4.3.2.4. Fragmented regulatory pathways and compliance burden
4.3.3. Key Opportunities
4.3.3.1. Longitudinal molecular residual disease and recurrence programs
4.3.3.2. Risk-stratified screening linked to complete diagnostic pathways
4.3.3.3. Localized hybrid laboratory networks in expanding and underserved regions
4.3.3.4. Integrated interpretation and multi-analyte workflow software
4.3.4. Key Challenges
4.3.4.1. Pre-analytical consistency across distributed specimen networks
4.3.4.2. Converting analytical performance into decision-changing clinical utility
4.3.4.3. Affordability, infrastructure, and equitable access constraints
4.3.4.4. Managing hybrid delivery, data, and portfolio complexity
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Liquid Biopsy Market, by Offering
7.1. Introduction
7.2. Testing Services
7.2.1. Clinical Testing Services
7.2.2. Biopharma & Research Testing Services
7.3. Products
7.3.1. Assay Kits & Reagents
7.3.2. Instruments & Integrated Systems
7.3.3. Analyte Isolation & Enrichment Products
7.3.4. Specimen Collection & Preservation Products
7.3.5. Bioinformatics & Interpretation Software
8. Liquid Biopsy Market, by Specimen
8.1. Introduction
8.2. Blood-Derived Specimens
8.2.1. Plasma
8.2.2. Whole Blood
8.2.3. Serum
8.3. Urine
8.4. Serous Cavity Fluids
8.4.1. Pleural Effusion
8.4.2. Ascites & Peritoneal Fluid
8.5. Cerebrospinal Fluid
8.6. Saliva & Oral Rinses
8.7. Ocular Fluids
9. Liquid Biopsy Market, by Target Analyte
9.1. Introduction
9.2. Cell-Free Nucleic Acids
9.2.1. Cell-Free DNA
9.2.1.1. Genomic Variant Signals
9.2.1.2. DNA Methylation Signals
9.2.1.3. Fragmentomic Signals
9.2.2. Cell-Free RNA
9.2.2.1. MicroRNA & Other Non-Coding RNA
9.2.2.2. Messenger RNA
9.3. Circulating Tumor Cells
9.4. Protein & Peptide Signatures
9.5. Multi-Analyte Signatures
9.6. Extracellular Vesicles
9.7. Circulating Chromatin & Nucleosomes
9.8. Metabolite & Glycan Signatures
10. Liquid Biopsy Market, by Analytical Platform
10.1. Introduction
10.2. Next-Generation Sequencing
10.2.1. Targeted Sequencing
10.2.2. Genome-Scale Sequencing
10.3. Polymerase Chain Reaction
10.3.1. Digital PCR
10.3.2. Real-Time PCR
10.4. Immunoassay
10.5. Rare-Cell Analysis
10.5.1. Affinity-Based Cell Enrichment
10.5.2. Physical-Property Cell Enrichment
10.5.3. Enrichment-Free Cell Imaging
10.6. Mass Spectrometry
11. Liquid Biopsy Market, by Application
11.1. Introduction
11.2. Molecular Profiling & Therapy Selection
11.3. Molecular Residual Disease & Recurrence Surveillance
11.4. Drug Development & Clinical Research
11.5. Screening & Early Detection
11.5.1. Multi-Cancer Early Detection
11.5.2. Single-Cancer Screening
11.6. Treatment Response & Resistance Monitoring
11.7. Prognosis & Risk Stratification
11.8. Diagnostic Resolution & Tumor Localization
12. Liquid Biopsy Market, by Cancer Indication
12.1. Introduction
12.2. Solid Tumor Coverage
12.2.1. Broad Solid-Tumor Coverage
12.2.2. Digestive System Cancers
12.2.3. Genitourinary Cancers
12.2.4. Breast Cancer
12.2.5. Thoracic Cancers
12.2.6. Gynecologic Cancers
12.2.7. Skin Cancers
12.2.8. Head & Neck Cancers
12.2.9. Brain & Central Nervous System Cancers
12.2.10. Endocrine Cancers
12.2.11. Cancers of Unknown Primary
12.2.12. Bone & Soft-Tissue Sarcomas
12.2.13. Ocular Cancers
12.3. Multi-Cancer Coverage
12.4. Hematologic Malignancies
13. Liquid Biopsy Market, by End User
13.1. Introduction
13.2. Healthcare Providers
13.2.1. Hospitals & Cancer Centers
13.2.2. Physician Practices & Specialty Clinics
13.3. Clinical Laboratories
13.3.1. Independent & Specialty Laboratories
13.3.2. Hospital & Health-System Laboratories
13.4. Life Sciences Companies & Contract Research Organizations
13.5. Academic & Translational Research Institutions
13.6. Health Plans & Employer Programs
13.7. Government & Population-Screening Programs
14. Liquid Biopsy Market, by Delivery Model
14.1. Introduction
14.2. Centralized Provider-Operated Testing
14.3. Decentralized Customer-Laboratory Testing
14.3.1. Fully On-Premises Deployment
14.3.2. Cloud-Assisted Deployment
15. Liquid Biopsy Market, by Region
15.1. Introduction
15.2. North America
15.3. Europe
15.4. Asia-Pacific
15.5. Latin America
15.6. Middle East
15.7. Africa
16. Liquid Biopsy Market, by Group
16.1. Introduction
16.2. NATO
16.3. G7
16.4. European Union
16.5. BRICS
16.6. ASEAN
16.7. GCC
17. Liquid Biopsy Market, by Country
17.1. Introduction
17.2. United States
17.3. China
17.4. Japan
17.5. Germany
17.6. United Kingdom
17.7. France
17.8. Italy
17.9. Canada
17.10. Brazil
17.11. South Korea
17.12. Spain
17.13. Australia
17.14. India
17.15. Russia
17.16. Mexico
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. Market Concentration Analysis, 2025
18.2.1. Concentration Ratio (CR)
18.2.2. Herfindahl Hirschman Index (HHI)
18.3. Recent Developments & Impact Analysis, 2025
18.4. Product Portfolio Analysis, 2025
18.5. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Guardant Health, Inc.
19.2. Foundation Medicine, Inc.
19.3. Natera, Inc.
19.4. GRAIL, Inc.
19.5. Abbott Laboratories
19.6. Tempus AI, Inc.
19.7. Illumina, Inc.
19.8. Thermo Fisher Scientific Inc.
19.9. QIAGEN N.V.
19.10. Menarini Silicon Biosystems
19.11. Sysmex Corporation
19.12. Caris Life Sciences, Inc.
19.13. Labcorp Holdings Inc.
19.14. Quest Diagnostics Incorporated
19.15. Burning Rock Biotech Limited
19.16. ANGLE plc
19.17. Lucence
19.18. Mirxes Holding Company Limited
19.19. Geneseeq Technology Inc.
19.20. MedGenome
19.21. Freenome, Inc.
19.22. Personalis, Inc.
19.23. NeoGenomics Laboratories, Inc.
19.24. BillionToOne, Inc.
19.25. DELFI Diagnostics, Inc.
19.26. Gene Solutions Genomics Pte. Ltd.
20. Key Experts
List of Figures
FIGURE 1. Global Liquid Biopsy Market, Years Considered for the Study
FIGURE 2. Global Liquid Biopsy Market, Research Design
FIGURE 3. Global Liquid Biopsy Market, Research Framework
FIGURE 4. Global Liquid Biopsy Market, Data Triangulation
FIGURE 5. Global Liquid Biopsy Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Liquid Biopsy Market Size, by Offering, 2025 vs 2032 (%)
FIGURE 7. Global Liquid Biopsy Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Liquid Biopsy Market Size, by Specimen, 2025 vs 2032 (%)
FIGURE 9. Global Liquid Biopsy Market Size, by Specimen, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Liquid Biopsy Market Size, by Target Analyte, 2025 vs 2032 (%)
FIGURE 11. Global Liquid Biopsy Market Size, by Target Analyte, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Liquid Biopsy Market Size, by Analytical Platform, 2025 vs 2032 (%)
FIGURE 13. Global Liquid Biopsy Market Size, by Analytical Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Liquid Biopsy Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global Liquid Biopsy Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Liquid Biopsy Market Size, by Cancer Indication, 2025 vs 2032 (%)
FIGURE 17. Global Liquid Biopsy Market Size, by Cancer Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Liquid Biopsy Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Liquid Biopsy Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Liquid Biopsy Market Size, by Delivery Model, 2025 vs 2032 (%)
FIGURE 21. Global Liquid Biopsy Market Size, by Delivery Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Liquid Biopsy Market Size, by Region, 2025 vs 2032 (%)
FIGURE 23. Global Liquid Biopsy Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Liquid Biopsy Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Liquid Biopsy Market Size, by Country, 2025 vs 2032 (%)
FIGURE 26. Global Liquid Biopsy Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Liquid Biopsy Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Liquid Biopsy Market Segmentation & Coverage
TABLE 2. Global Liquid Biopsy Market Size, 2017-2032 (USD Million)
TABLE 3. Global Liquid Biopsy Market Size, by Offering, 2017-2032 (USD Million)
TABLE 4. Global Testing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Testing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Testing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Clinical Testing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Clinical Testing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Clinical Testing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Biopharma & Research Testing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Biopharma & Research Testing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Biopharma & Research Testing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Assay Kits & Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Assay Kits & Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Assay Kits & Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Instruments & Integrated Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Instruments & Integrated Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Instruments & Integrated Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Analyte Isolation & Enrichment Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Analyte Isolation & Enrichment Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Analyte Isolation & Enrichment Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Specimen Collection & Preservation Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Specimen Collection & Preservation Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Specimen Collection & Preservation Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Bioinformatics & Interpretation Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Bioinformatics & Interpretation Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Bioinformatics & Interpretation Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Liquid Biopsy Market Size, by Specimen, 2017-2032 (USD Million)
TABLE 32. Global Blood-Derived Specimens Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Blood-Derived Specimens Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Blood-Derived Specimens Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Plasma Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Plasma Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Plasma Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Whole Blood Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Whole Blood Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Whole Blood Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Serum Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Serum Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Serum Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Urine Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Urine Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Urine Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Serous Cavity Fluids Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Serous Cavity Fluids Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Serous Cavity Fluids Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Pleural Effusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Pleural Effusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Pleural Effusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Ascites & Peritoneal Fluid Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Ascites & Peritoneal Fluid Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Ascites & Peritoneal Fluid Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Cerebrospinal Fluid Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Cerebrospinal Fluid Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Cerebrospinal Fluid Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Saliva & Oral Rinses Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Saliva & Oral Rinses Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Saliva & Oral Rinses Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Ocular Fluids Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Ocular Fluids Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Ocular Fluids Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Liquid Biopsy Market Size, by Target Analyte, 2017-2032 (USD Million)
TABLE 66. Global Cell-Free Nucleic Acids Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Cell-Free Nucleic Acids Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Cell-Free Nucleic Acids Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Cell-Free DNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Cell-Free DNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Cell-Free DNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Genomic Variant Signals Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Genomic Variant Signals Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Genomic Variant Signals Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global DNA Methylation Signals Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global DNA Methylation Signals Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global DNA Methylation Signals Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Fragmentomic Signals Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Fragmentomic Signals Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Fragmentomic Signals Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Cell-Free RNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Cell-Free RNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Cell-Free RNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global MicroRNA & Other Non-Coding RNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global MicroRNA & Other Non-Coding RNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global MicroRNA & Other Non-Coding RNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Messenger RNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Messenger RNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Messenger RNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Circulating Tumor Cells Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Circulating Tumor Cells Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Circulating Tumor Cells Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Protein & Peptide Signatures Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Protein & Peptide Signatures Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Protein & Peptide Signatures Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Multi-Analyte Signatures Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Multi-Analyte Signatures Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Multi-Analyte Signatures Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Extracellular Vesicles Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Extracellular Vesicles Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Extracellular Vesicles Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Circulating Chromatin & Nucleosomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Circulating Chromatin & Nucleosomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Circulating Chromatin & Nucleosomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Metabolite & Glycan Signatures Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Metabolite & Glycan Signatures Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Metabolite & Glycan Signatures Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Liquid Biopsy Market Size, by Analytical Platform, 2017-2032 (USD Million)
TABLE 109. Global Next-Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Next-Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Next-Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Targeted Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Targeted Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Targeted Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Genome-Scale Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Genome-Scale Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Genome-Scale Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Digital PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Digital PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Digital PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Real-Time PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Real-Time PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Real-Time PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Rare-Cell Analysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Rare-Cell Analysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Rare-Cell Analysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Affinity-Based Cell Enrichment Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Affinity-Based Cell Enrichment Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Affinity-Based Cell Enrichment Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global Physical-Property Cell Enrichment Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Global Physical-Property Cell Enrichment Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. Global Physical-Property Cell Enrichment Market Size, by Country, 2017-2032 (USD Million)
TABLE 139. Global Enrichment-Free Cell Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. Global Enrichment-Free Cell Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. Global Enrichment-Free Cell Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 142. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 145. Global Liquid Biopsy Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. Global Molecular Profiling & Therapy Selection Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Molecular Profiling & Therapy Selection Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Molecular Profiling & Therapy Selection Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Molecular Residual Disease & Recurrence Surveillance Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Molecular Residual Disease & Recurrence Surveillance Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Molecular Residual Disease & Recurrence Surveillance Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Drug Development & Clinical Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Drug Development & Clinical Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Drug Development & Clinical Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Screening & Early Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Global Screening & Early Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. Global Screening & Early Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 158. Global Multi-Cancer Early Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Global Multi-Cancer Early Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. Global Multi-Cancer Early Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. Global Single-Cancer Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Single-Cancer Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Single-Cancer Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Treatment Response & Resistance Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Treatment Response & Resistance Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Treatment Response & Resistance Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global Prognosis & Risk Stratification Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Prognosis & Risk Stratification Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Prognosis & Risk Stratification Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Diagnostic Resolution & Tumor Localization Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Diagnostic Resolution & Tumor Localization Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Diagnostic Resolution & Tumor Localization Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Liquid Biopsy Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 174. Global Solid Tumor Coverage Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. Global Solid Tumor Coverage Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. Global Solid Tumor Coverage Market Size, by Country, 2017-2032 (USD Million)
TABLE 177. Global Broad Solid-Tumor Coverage Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Global Broad Solid-Tumor Coverage Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. Global Broad Solid-Tumor Coverage Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. Global Digestive System Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Global Digestive System Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. Global Digestive System Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 183. Global Genitourinary Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 184. Global Genitourinary Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. Global Genitourinary Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 186. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 189. Global Thoracic Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 190. Global Thoracic Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. Global Thoracic Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 192. Global Gynecologic Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Global Gynecologic Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. Global Gynecologic Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 195. Global Skin Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 196. Global Skin Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. Global Skin Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 198. Global Head & Neck Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Global Head & Neck Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. Global Head & Neck Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 201. Global Brain & Central Nervous System Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 202. Global Brain & Central Nervous System Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 203. Global Brain & Central Nervous System Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 204. Global Endocrine Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 205. Global Endocrine Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 206. Global Endocrine Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 207. Global Cancers of Unknown Primary Market Size, by Region, 2017-2032 (USD Million)
TABLE 208. Global Cancers of Unknown Primary Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. Global Cancers of Unknown Primary Market Size, by Country, 2017-2032 (USD Million)
TABLE 210. Global Bone & Soft-Tissue Sarcomas Market Size, by Region, 2017-2032 (USD Million)
TABLE 211. Global Bone & Soft-Tissue Sarcomas Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. Global Bone & Soft-Tissue Sarcomas Market Size, by Country, 2017-2032 (USD Million)
TABLE 213. Global Ocular Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 214. Global Ocular Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. Global Ocular Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 216. Global Multi-Cancer Coverage Market Size, by Region, 2017-2032 (USD Million)
TABLE 217. Global Multi-Cancer Coverage Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. Global Multi-Cancer Coverage Market Size, by Country, 2017-2032 (USD Million)
TABLE 219. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 220. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 222. Global Liquid Biopsy Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. Global Healthcare Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Global Healthcare Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. Global Healthcare Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 226. Global Hospitals & Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Global Hospitals & Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. Global Hospitals & Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 229. Global Physician Practices & Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 230. Global Physician Practices & Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. Global Physician Practices & Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 232. Global Clinical Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Global Clinical Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. Global Clinical Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 235. Global Independent & Specialty Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 236. Global Independent & Specialty Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. Global Independent & Specialty Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 238. Global Hospital & Health-System Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 239. Global Hospital & Health-System Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. Global Hospital & Health-System Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 241. Global Life Sciences Companies & Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Global Life Sciences Companies & Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. Global Life Sciences Companies & Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 244. Global Academic & Translational Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. Global Academic & Translational Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. Global Academic & Translational Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 247. Global Health Plans & Employer Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Global Health Plans & Employer Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. Global Health Plans & Employer Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. Global Government & Population-Screening Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 251. Global Government & Population-Screening Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. Global Government & Population-Screening Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. Global Liquid Biopsy Market Size, by Delivery Model, 2017-2032 (USD Million)
TABLE 254. Global Centralized Provider-Operated Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 255. Global Centralized Provider-Operated Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 256. Global Centralized Provider-Operated Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 257. Global Decentralized Customer-Laboratory Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 258. Global Decentralized Customer-Laboratory Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. Global Decentralized Customer-Laboratory Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 260. Global Fully On-Premises Deployment Market Size, by Region, 2017-2032 (USD Million)
TABLE 261. Global Fully On-Premises Deployment Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. Global Fully On-Premises Deployment Market Size, by Country, 2017-2032 (USD Million)
TABLE 263. Global Cloud-Assisted Deployment Market Size, by Region, 2017-2032 (USD Million)
TABLE 264. Global Cloud-Assisted Deployment Market Size, by Group, 2017-2032 (USD Million)
TABLE 265. Global Cloud-Assisted Deployment Market Size, by Country, 2017-2032 (USD Million)
TABLE 266. Global Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 267. North America Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 268. North America Liquid Biopsy Market Size, by Offering, 2017-2032 (USD Million)
TABLE 269. North America Liquid Biopsy Market Size, by Testing Services, 2017-2032 (USD Million)
TABLE 270. North America Liquid Biopsy Market Size, by Products, 2017-2032 (USD Million)
TABLE 271. North America Liquid Biopsy Market Size, by Specimen, 2017-2032 (USD Million)
TABLE 272. North America Liquid Biopsy Market Size, by Blood-Derived Specimens, 2017-2032 (USD Million)
TABLE 273. North America Liquid Biopsy Market Size, by Serous Cavity Fluids, 2017-2032 (USD Million)
TABLE 274. North America Liquid Biopsy Market Size, by Target Analyte, 2017-2032 (USD Million)
TABLE 275. North America Liquid Biopsy Market Size, by Cell-Free Nucleic Acids, 2017-2032 (USD Million)
TABLE 276. North America Liquid Biopsy Market Size, by Cell-Free DNA, 2017-2032 (USD Million)
TABLE 277. North America Liquid Biopsy Market Size, by Cell-Free RNA, 2017-2032 (USD Million)
TABLE 278. North America Liquid Biopsy Market Size, by Analytical Platform, 2017-2032 (USD Million)
TABLE 279. North America Liquid Biopsy Market Size, by Next-Generation Sequencing, 2017-2032 (USD Million)
TABLE 280. North America Liquid Biopsy Market Size, by Polymerase Chain Reaction, 2017-2032 (USD Million)
TABLE 281. North America Liquid Biopsy Market Size, by Rare-Cell Analysis, 2017-2032 (USD Million)
TABLE 282. North America Liquid Biopsy Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. North America Liquid Biopsy Market Size, by Screening & Early Detection, 2017-2032 (USD Million)
TABLE 284. North America Liquid Biopsy Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 285. North America Liquid Biopsy Market Size, by Solid Tumor Coverage, 2017-2032 (USD Million)
TABLE 286. North America Liquid Biopsy Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. North America Liquid Biopsy Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 288. North America Liquid Biopsy Market Size, by Clinical Laboratories, 2017-2032 (USD Million)
TABLE 289. North America Liquid Biopsy Market Size, by Delivery Model, 2017-2032 (USD Million)
TABLE 290. North America Liquid Biopsy Market Size, by Decentralized Customer-Laboratory Testing, 2017-2032 (USD Million)
TABLE 291. Europe Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 292. Europe Liquid Biopsy Market Size, by Offering, 2017-2032 (USD Million)
TABLE 293. Europe Liquid Biopsy Market Size, by Testing Services, 2017-2032 (USD Million)
TABLE 294. Europe Liquid Biopsy Market Size, by Products, 2017-2032 (USD Million)
TABLE 295. Europe Liquid Biopsy Market Size, by Specimen, 2017-2032 (USD Million)
TABLE 296. Europe Liquid Biopsy Market Size, by Blood-Derived Specimens, 2017-2032 (USD Million)
TABLE 297. Europe Liquid Biopsy Market Size, by Serous Cavity Fluids, 2017-2032 (USD Million)
TABLE 298. Europe Liquid Biopsy Market Size, by Target Analyte, 2017-2032 (USD Million)
TABLE 299. Europe Liquid Biopsy Market Size, by Cell-Free Nucleic Acids, 2017-2032 (USD Million)
TABLE 300. Europe Liquid Biopsy Market Size, by Cell-Free DNA, 2017-2032 (USD Million)
TABLE 301. Europe Liquid Biopsy Market Size, by Cell-Free RNA, 2017-2032 (USD Million)
TABLE 302. Europe Liquid Biopsy Market Size, by Analytical Platform, 2017-2032 (USD Million)
TABLE 303. Europe Liquid Biopsy Market Size, by Next-Generation Sequencing, 2017-2032 (USD Million)
TABLE 304. Europe Liquid Biopsy Market Size, by Polymerase Chain Reaction, 2017-2032 (USD Million)
TABLE 305. Europe Liquid Biopsy Market Size, by Rare-Cell Analysis, 2017-2032 (USD Million)
TABLE 306. Europe Liquid Biopsy Market Size, by Application, 2017-2032 (USD Million)
TABLE 307. Europe Liquid Biopsy Market Size, by Screening & Early Detection, 2017-2032 (USD Million)
TABLE 308. Europe Liquid Biopsy Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 309. Europe Liquid Biopsy Market Size, by Solid Tumor Coverage, 2017-2032 (USD Million)
TABLE 310. Europe Liquid Biopsy Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. Europe Liquid Biopsy Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 312. Europe Liquid Biopsy Market Size, by Clinical Laboratories, 2017-2032 (USD Million)
TABLE 313. Europe Liquid Biopsy Market Size, by Delivery Model, 2017-2032 (USD Million)
TABLE 314. Europe Liquid Biopsy Market Size, by Decentralized Customer-Laboratory Testing, 2017-2032 (USD Million)
TABLE 315. Asia-Pacific Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 316. Asia-Pacific Liquid Biopsy Market Size, by Offering, 2017-2032 (USD Million)
TABLE 317. Asia-Pacific Liquid Biopsy Market Size, by Testing Services, 2017-2032 (USD Million)
TABLE 318. Asia-Pacific Liquid Biopsy Market Size, by Products, 2017-2032 (USD Million)
TABLE 319. Asia-Pacific Liquid Biopsy Market Size, by Specimen, 2017-2032 (USD Million)
TABLE 320. Asia-Pacific Liquid Biopsy Market Size, by Blood-Derived Specimens, 2017-2032 (USD Million)
TABLE 321. Asia-Pacific Liquid Biopsy Market Size, by Serous Cavity Fluids, 2017-2032 (USD Million)
TABLE 322. Asia-Pacific Liquid Biopsy Market Size, by Target Analyte, 2017-2032 (USD Million)
TABLE 323. Asia-Pacific Liquid Biopsy Market Size, by Cell-Free Nucleic Acids, 2017-2032 (USD Million)
TABLE 324. Asia-Pacific Liquid Biopsy Market Size, by Cell-Free DNA, 2017-2032 (USD Million)
TABLE 325. Asia-Pacific Liquid Biopsy Market Size, by Cell-Free RNA, 2017-2032 (USD Million)
TABLE 326. Asia-Pacific Liquid Biopsy Market Size, by Analytical Platform, 2017-2032 (USD Million)
TABLE 327. Asia-Pacific Liquid Biopsy Market Size, by Next-Generation Sequencing, 2017-2032 (USD Million)
TABLE 328. Asia-Pacific Liquid Biopsy Market Size, by Polymerase Chain Reaction, 2017-2032 (USD Million)
TABLE 329. Asia-Pacific Liquid Biopsy Market Size, by Rare-Cell Analysis, 2017-2032 (USD Million)
TABLE 330. Asia-Pacific Liquid Biopsy Market Size, by Application, 2017-2032 (USD Million)
TABLE 331. Asia-Pacific Liquid Biopsy Market Size, by Screening & Early Detection, 2017-2032 (USD Million)
TABLE 332. Asia-Pacific Liquid Biopsy Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 333. Asia-Pacific Liquid Biopsy Market Size, by Solid Tumor Coverage, 2017-2032 (USD Million)
TABLE 334. Asia-Pacific Liquid Biopsy Market Size, by End User, 2017-2032 (USD Million)
TABLE 335. Asia-Pacific Liquid Biopsy Market Size, by Healthcare Providers, 2017-2032 (USD Million)
TABLE 336. Asia-Pacific Liquid Biopsy Market Size, by Clinical Laboratories, 2017-2032 (USD Million)
TABLE 337. Asia-Pacific Liquid Biopsy Market Size, by Delivery Model, 2017-2032 (USD Million)
TABLE 338. Asia-Pacific Liquid Biopsy Market Size, by Decentralized Customer-Laboratory Testing, 2017-2032 (USD Million)
TABLE 339. Latin America Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 340. Latin America Liquid Biopsy Market Size, by Offering, 2017-2032 (USD Million)
TABLE 341. Latin America Liquid Biopsy Market Size, by Testing Services, 2017-2032 (USD Million)
TABLE 342. Latin America Liquid Biopsy Market Size, by Products, 2017-2032 (USD Million)
TABLE 343. Latin America Liquid Biopsy Market Size, by Specimen, 2017-2032 (USD Million)
TABLE 344. Latin America Liquid Biopsy Market Size, by Blood-Derived Specimens, 2017-2032 (USD Million)
TABLE 345. Latin America Liquid Biopsy Market Size, by Serous Cavity Fluids, 2017-2032 (USD Million)
TABLE 346. Latin America Liquid Biopsy Market Size, by Target Analyte, 2017-2032 (USD Million)
TABLE 347. Latin America Liquid Biopsy Market Size, by Cell-Free Nucleic Acids, 2017-2032 (USD Million)
TABLE 348. Latin America Liquid Biopsy Market Size, by Cell-Free DNA, 2017-2032 (USD Million)
TABLE 349. Latin America Liquid Biopsy Market Size, by Cell-Free RNA, 2017-2032 (USD Million)
TABLE 350. Latin America Liquid Biopsy Market Size, by Analytical Platform, 2017-2032 (USD Million)
TABLE 351. Latin America Liquid Biopsy Market Size, by Next-Generation Sequencing, 2017-2032 (USD Million)
TABLE 352. Latin America Liquid Biopsy Market Size, by Polymerase Chain Reaction, 2017-2032 (USD Million)
TABLE 353. Latin America Liquid Biopsy Market Size, by Rare-Cell Analysis, 2017-2032 (USD Million)
TABLE 354. Latin America Liquid Biopsy Market Size, by Application, 2017-2032 (USD Million)
TABLE 355

Companies Mentioned

  • Guardant Health, Inc.
  • Foundation Medicine, Inc.
  • Natera, Inc.
  • GRAIL, Inc.
  • Abbott Laboratories
  • Tempus AI, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Menarini Silicon Biosystems
  • Sysmex Corporation
  • Caris Life Sciences, Inc.
  • Labcorp Holdings Inc.
  • Quest Diagnostics Incorporated
  • Burning Rock Biotech Limited
  • ANGLE plc
  • MDxHealth SA
  • Lucence
  • Mirxes Holding Company Limited
  • AnchorDx
  • Geneseeq Technology Inc.
  • HaploX Ltd.
  • Datar Cancer Genetics
  • MedGenome
  • Strand Life Sciences
  • Geneseq Biosciences
  • INOVIQ Limited
  • GC Genome
  • Freenome, Inc.
  • ClearNote Health
  • Epic Sciences, Inc.
  • Personalis, Inc.
  • OncoDNA
  • SOPHiA GENETICS SA
  • NeoGenomics Laboratories, Inc.
  • Biodesix, Inc.
  • Predicine, Inc.
  • BillionToOne, Inc.
  • DELFI Diagnostics, Inc.
  • Harbinger Health, Inc.
  • Adela, Inc.
  • Mercy BioAnalytics, Inc.
  • Gene Solutions Genomics Pte. Ltd.
  • Helio Genomics
  • Singlera Genomics Inc.
  • RareCyte, Inc.
  • ScreenCell
  • Precede Biosciences, Inc.
  • Exai Bio, Inc.
  • Elypta AB
  • VolitionRx Limited
  • DiaCarta, Inc.
  • Streck

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Global Strategic Business Report - Product Image

Breast Cancer Liquid Biopsy - Global Strategic Business Report

  • Report
  • 217 Pages
  • Global
From
Liquid Biopsy for Cancer Diagnostics Market Report 2026 - Product Image

Liquid Biopsy for Cancer Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Breast Cancer Liquid Biopsy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 135 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.